Amphetamines represent one of the most clinically potent and pharmacologically transformative classes of central nervous system stimulants synthesized in the modern era. Operating fundamentally as indirect sympathomimetic agents, these compounds dramatically recalibrate monoaminergic neurotransmission, producing marked increases in wakefulness, executive focus, vigilance, and physical endurance. Yet, this profound capacity to optimize neurocognitive performance exists in constant tension with substantial liabilities of dependence, neurotoxicity, and systemic physiological strain, making amphetamines a subject of enduring debate across clinical psychiatry, neurobiology, and public health policy.
Amphetamines
1. Concise Definition
Amphetamines are a class of synthetic phenethylamine derivatives that act as potent central nervous system (CNS) stimulants by functioning primarily as substrate-type releasers of the catecholamines dopamine and norepinephrine. Structurally centered around alpha-methylphenethylamine, these compounds exert their biological effects by crossing cellular membranes, binding to intracellular targets, and inverting the directional transport of monoamine carrier proteins. Therapeutically, amphetamines are classified as Schedule II controlled substances in the United States and Class B drugs in the United Kingdom, recognized for their efficacy in managing neurodevelopmental and sleep-wake disorders.
Beyond their basic structural designation, the term amphetamines broadly encompasses both the parent molecule—racemic amphetamine—its individual enantiomers (dextroamphetamine and levoamphetamine), prodrug formulations (such as lisdexamfetamine), and a diverse family of substituted derivatives. At therapeutic doses, they elevate cortical arousal and optimize prefrontal network connectivity, facilitating executive control and sustained attention. Conversely, at supra-therapeutic or chronic recreational doses, they precipitate extensive monoaminergic surges that can induce severe cardiovascular toxicity, behavioral stereotypic patterns, psychosis, and pronounced physiological dependence.
2. Etymology & Linguistic Origin
The term amphetamine is a chemical portmanteau coined through the condensation of its systematic chemical nomenclature: alpha-methylphenethylamine (a-m-ph-et-amine). The compound was initially synthesized in 1887 by the Romanian chemist Lazăr Edeleanu at the University of Berlin, who originally documented the clear, oily basic liquid as phenylisopropylamin.
The anglicized contraction amphetamine was popularized in the early 1930s when the American biochemist Gordon Alles investigated its physiological properties while seeking a synthetic substitute for ephedrine. Shortly thereafter, the pharmaceutical company Smith, Kline & French commercialized the compound under the registered trademark Benzedrine. Over subsequent decades, the contracted term evolved from a proprietary trade shorthand into the universally accepted international nonproprietary name (INN) and biomedical category used to designate this specific pharmacological class.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed in International Phonetic Alphabet (IPA) as /æmˈfɛt.ə.miːn/ in American English and /æmˈfɛt.ə.mɪn/ in British English.
Grammatical Form: Noun (singular: amphetamine; plural: amphetamines). It functions both as an uncountable noun referring to the chemical compound itself and as a countable noun referring to specific pharmaceutical preparations or substituted structural analogues. The adjectival derivation is amphetaminergic (referring to physiological systems, neural circuits, or pharmacological actions stimulated by or responsive to amphetamines).
4. Detailed Conceptual Explanation
The pharmacodynamics of amphetamines distinguish them fundamentally from simple reuptake inhibitors like cocaine or methylphenidate. While classic reuptake inhibitors merely plug transport proteins to prevent the clearance of monoamines from the synaptic cleft, amphetamines act as permeable transporter substrates. Upon crossing the blood-brain barrier via passive diffusion and carrier-mediated transport, amphetamines utilize the dopamine transporter (DAT), norepinephrine transporter (NET), and to a substantially lesser extent the serotonin transporter (SERT) to gain entry into the presynaptic terminal.
Once inside the presynaptic cytoplasm, amphetamine activates an intracellular G-protein-coupled receptor known as trace amine-associated receptor 1 (TAAR1). The activation of TAAR1 triggers protein kinase A (PKA) and protein kinase C (PKC) signaling cascades, which induce the phosphorylation of DAT and NET. This phosphorylation induces a profound conformational change: the transporters undergo inward-facing to outward-facing inversions, effectively operating in reverse to pump cytoplasmic catecholamines directly into the synaptic cleft independently of normal action-potential-mediated exocytosis.
Concurrently, amphetamines penetrate presynaptic storage vesicles by diffusing across the vesicular membrane or utilizing the vesicular monoamine transporter 2 (VMAT2). Inside the vesicle, amphetamine acts as a weak base, buffering the acidic intravesicular pH gradient that powers the proton-ATPase pump responsible for sequestering monoamines. Deprived of this electrochemical gradient, VMAT2 ceases uptake and collapses, releasing massive quantities of intravesicular dopamine and norepinephrine into the presynaptic cytoplasm. This newly liberated pool of cytosolic transmitter is subsequently expelled into the extracellular synapse via the phosphorylated, reverse-operating surface transporters.
The resulting massive surge of synaptic dopamine within the mesocorticolimbic pathway (connecting the ventral tegmental area to the nucleus accumbens) mediates the profound reinforcing, euphoric, and locomotor-stimulating properties of the drug. Concurrently, heightened norepinephrine and dopamine release within the prefrontal cortex optimizes signal-to-noise ratios in pyramidal neurons, strengthening working memory, sustained attention, and inhibitory control at therapeutic concentrations. Systemically, peripheral release of norepinephrine from sympathetic postganglionic fibers stimulates alpha-1, beta-1, and beta-2 adrenergic receptors, producing tachycardia, peripheral vasoconstriction, pupillary dilation, and elevated arterial blood pressure.
Pharmacokinetically, amphetamine demonstrates high oral bioavailability (typically 75% to 80%) with low plasma protein binding (approximately 20%). The drug is lipophilic, allowing rapid parenchymal brain penetration. Hepatic metabolism occurs predominantly via deamination mediated by CYP2D6 to form phenylacetone, which is subsequently oxidized to benzoic acid and excreted as hippuric acid. A significant fraction of amphetamine is excreted completely unchanged by the kidneys. Renal elimination is highly pH-dependent: acidic urine accelerates excretion, shortening the elimination half-life to approximately 7 to 11 hours, whereas alkaline urine promotes tubular reabsorption, prolonging the half-life up to 30 hours or more.
5. Historical Development
Following Lazăr Edeleanu’s initial synthesis of racemic amphetamine in 1887, the substance remained biologically uncharacterized for four decades. In 1927, chemist Gordon Alles re-synthesized the compound in California while attempting to discover an inexpensive, orally active bronchodilator to replace naturally extracted ephedrine. Alles noted that the substance induced dramatic subjective alertness, insomnia, and blood pressure elevation, recognizing its broader psychotropic potential.
By 1932, the pharmaceutical company Smith, Kline & French obtained commercial rights to Alles’s discovery and patented the volatile free base formulation as the Benzedrine inhaler, marketing it for nasal congestion and asthma. Physicians quickly observed that patients were extracting the amphetamine-soaked paper strips from inhalers to ingest them for wakefulness and euphoria. In 1937, the American psychiatrist Charles Bradley conducted a landmark clinical trial at the Emma Pendleton Bradley Home in Rhode Island, administering Benzedrine to children presenting with severe behavioral challenges and learning difficulties. Bradley observed remarkable improvements in school performance, attention span, and impulse regulation, an empirical finding that established the clinical foundation for treating what is now recognized as Attention-Deficit/Hyperactivity Disorder (ADHD).
World War II catalyzed the global industrialization of amphetamine production. Military commands on both sides of the conflict distributed stimulants systematically to combat personnel. The German military dispensed millions of tablets of methamphetamine (Pervitin) during the Blitzkrieg campaigns, while British and American forces widely issued dextroamphetamine (Dexedrine) and Benzedrine to aviators, tank crews, and infantry to combat exhaustion and sustain operational performance during prolonged engagements.
The post-war era precipitated widespread public health epidemics of amphetamine abuse, particularly in Japan—where military stockpiles were dumped onto civilian markets—and later across Europe and North America. By the 1960s, illicit diversion and the emergence of intravenous use (“speed”) prompted international regulatory crackdowns. In the United States, the passage of the Comprehensive Drug Abuse Prevention and Control Act of 1970 classified amphetamines as Schedule II controlled substances, severely restricting production quotas and clinical indications. The 1990s and 2000s witnessed a major renaissance in medical amphetamine utilization, driven by refined diagnostic criteria for ADHD across the lifespan and the engineering of advanced extended-release delivery systems and prodrugs designed to minimize peak-to-trough fluctuations and curb misuse liability.
6. Theoretical Foundations
The understanding of amphetamine action relies heavily on several integrated neurobiological frameworks:
The Catecholamine Hypothesis of Executive Function provides the core rationale for therapeutic amphetamine use in psychiatric disorders. Grounded in the work of neuroscientists such as Amy Arnsten, this framework posits that prefrontal cortical (PFC) networks function optimally under moderate levels of dopamine and norepinephrine signaling, mapping onto an inverted-U dose-response curve. Insufficient catecholaminergic stimulation causes cognitive disorganization, distractibility, and impulsivity due to inadequate signal transmission in cortical circuits. Amphetamines normalize this deficiency by increasing synaptic dopamine (which stimulates D1 receptors to suppress network “noise”) and norepinephrine (which stimulates alpha-2A adrenergic receptors to strengthen network “signals”). However, excessive doses push the system past the peak of the inverted-U, inducing cognitive inflexibility, stereotypy, and hyperarousal.
The Incentive-Sensitization Theory of Addiction, formulated by Terry Robinson and Kent Berridge, explains the neuroadaptive shifts driving amphetamine dependence. This model demonstrates that repeated, intermittent exposure to high concentrations of amphetamines produces persistent neurochemical and structural neuroadaptations within mesolimbic circuits. Specifically, it hypersensitizes the dopaminergic “wanting” system (incentive salience) without augmenting the opioid-mediated “liking” system (hedonic impact). Over time, environmental cues associated with drug administration trigger intense craving and compulsive drug-seeking behavior, even when the subjective pleasure derived from the compound has experienced profound tolerance.
The Opponent-Process Theory, advanced by Richard Solomon, describes the homeostatic counter-adaptations precipitated by amphetamine administration. The initial positive, euphorigenic, and energizing “a-process” triggers an acute, compensatory physiological “b-process” designed to restore neurochemical equilibrium. With repeated use, the compensatory b-process strengthens, activates faster, and decays more slowly, manifesting clinically as physical tolerance, emotional blunting, profound fatigue, and anhedonia during acute withdrawal.
7. Key Components, Types & Dimensions
The amphetamine class comprises various chemical forms, optical isomers, and clinical preparations that vary in their receptor affinity, pharmacokinetic profiles, and therapeutic applications:
- Dextroamphetamine (d-amphetamine): The dextrorotatory, right-handed enantiomer of amphetamine. It exhibits three to four times greater potency in releasing dopamine compared to the levorotatory isomer, rendering it significantly more active as a CNS stimulant, cognitive enhancer, and reinforcer.
- Levoamphetamine (l-amphetamine): The levorotatory, left-handed enantiomer. It possesses substantially greater relative affinity for the norepinephrine transporter than for the dopamine transporter, mediating pronounced peripheral sympathomimetic effects including vasoconstriction, cardiovascular acceleration, and peripheral arousal, with comparatively weaker central euphoriant properties.
- Racemic Amphetamine: An equimolar (50:50) mixture of dextroamphetamine and levoamphetamine, originally marketed as Benzedrine. It provides an equal blend of central cognitive activation and peripheral autonomic arousal.
- Mixed Amphetamine Salts (Adderall): A proprietary formulation consisting of a 3:1 ratio of dextroamphetamine to levoamphetamine salts (neutral sulfate of dextroamphetamine, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate). This ratio aims to combine central executive enhancement with sufficient peripheral tone to prolong wakefulness.
- Lisdexamfetamine (Vyvanse): A biologically inert prodrug in which d-amphetamine is covalently bonded to the essential amino acid L-lysine. Following ingestion, rate-limited enzymatic cleavage by aminopeptidases within red blood cells cleaves the peptide bond, gradually releasing active d-amphetamine into systemic circulation. This mechanism prevents rapid euphoric spikes when injected or insufflated, reducing abuse potential.
- Substituted Amphetamines: A vast structural family containing modifications on the phenyl ring, the side chain, or the amino group. This subclass includes potent neurotoxic illicit stimulants like methamphetamine (N-methylamphetamine), entactogens like MDMA (3,4-methylenedioxymethamphetamine), and synthetic cathinones.
8. Examples & Illustrative Cases
The practical behavior of amphetamines across varying contexts can be illustrated through distinct clinical scenarios:
Case 1: Pediatric Attention-Deficit/Hyperactivity Disorder (Combined Type)
A 9-year-old child presents with chronic academic failure, disruptive classroom impulsivity, and executive dysfunction. Neuropsychological evaluation confirms ADHD. The clinician initiates treatment with lisdexamfetamine at a low dose (20 mg daily), titrating to 30 mg. Within two weeks, teachers document marked improvements in task completion, decreased vocal interruptions, and improved handwriting. The pharmacodynamic release profile provides smooth symptom coverage throughout the school day without late-afternoon behavioral rebound. Vital signs remain within normal parameters, though appetite suppression requires dietary adjustments to ensure adequate caloric intake during evening hours.
Case 2: Management of Narcolepsy Type 1
A 34-year-old adult diagnosed with narcolepsy accompanied by cataplexy suffers from severe excessive daytime sleepiness, experiencing sleep attacks during work meetings. The patient is prescribed mixed amphetamine salts extended-release (20 mg every morning) supplemented with a low-dose immediate-release tablet (5 mg) in the early afternoon. The regimen restores daytime alertness and functional occupational capacity by stimulating cortical dopamine and noradrenergic pathways, compensating for the endogenous deficit of hypothalamic hypocretin (orexin) signaling.
Case 3: Illicit Escalation and Stimulant-Induced Psychosis
A 22-year-old university student begins obtaining unprescribed mixed amphetamine salts to sustain nocturnal study sessions. Over six months, tolerance develops, prompting the individual to escalate dosages from 20 mg to 120 mg daily, eventually transitioning to intranasal insufflation. The individual arrives at an emergency department displaying extreme persecutory paranoia, auditory hallucinations, motor agitation, and diaphoresis. Clinical assessment confirms amphetamine-induced psychotic disorder without primary schizophrenia. Discontinuation of the stimulant, supportive hydration, and short-term administration of a dopamine D2 receptor antagonist (haloperidol) resolve the psychosis over 72 hours, revealing underlying dependence and profound post-cessation hypersomnia and dysphoria.
9. Measurement & Assessment
The monitoring, detection, and diagnostic assessment of amphetamines span clinical, psychiatric, and forensic methodologies:
In clinical psychiatric contexts, treatment efficacy for conditions like ADHD is quantified using validated behavioral rating scales, including the Adult ADHD Self-Report Scale (ASRS), the Conners’ Rating Scales, and the Clinical Global Impressions (CGI) scale. Baseline physical monitoring requires systematic recording of resting heart rate, blood pressure, body mass index, and growth curves in pediatric patients, alongside screening for occult cardiovascular abnormalities using family history algorithms or electrocardiography (ECG).
When assessing for substance use pathology, clinicians utilize the diagnostic criteria defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) for Amphetamine Use Disorder. Severity is graded based on the number of diagnostic criteria met over a 12-month period, spanning impaired control, social impairment, risky use, tolerance, and withdrawal.
Toxicological confirmation relies on initial urine drug screens using competitive enzyme-multiplied immunoassay techniques (EMIT). However, standard immunoassays are susceptible to false-positive results triggered by cross-reactive compounds with similar phenethylamine structures, including pseudoephedrine, bupropion, trazodone, ranitidine, and labetalol. Consequently, forensic or confirmatory testing requires definitive separation and identification via gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), which can differentiate between optical enantiomers (d- versus l-amphetamine) to verify whether detection stems from a prescribed pharmaceutical or an illicit source.
10. Applications & Practical Significance
In medicine, amphetamines serve as primary pharmacotherapies for several debilitating conditions. They remain first-line pharmacological treatments for ADHD across pediatric, adolescent, and adult populations, demonstrating some of the highest effect sizes (Cohen’s d ≈ 0.8 to 1.0) of any psychotropic intervention in clinical medicine. In sleep medicine, they are approved for narcolepsy and idiopathic hypersomnia, reversing daytime sleepiness. In 2015, the US Food and Drug Administration (FDA) approved lisdexamfetamine as the first pharmacological agent for moderate-to-severe Binge Eating Disorder (BED), where its actions on hypothalamic and striatal pathways help suppress compulsive eating episodes.
Outside traditional clinical boundaries, amphetamines hold significant operational utility in military aviation and specialized defense operations, where they have been utilized as “go-pills” under strict medical oversight to sustain alertness in pilots undertaking extended combat missions. In civil society, amphetamines occupy a controversial position as cognitive enhancers or “neuroenhancers.” On university campuses and within competitive professional sectors, their off-label diversion for academic doping has spurred intense bioethical debates regarding distributive fairness, coercion, and the medicalization of human productivity.
11. Research & Empirical Evidence
Extensive neuroimaging and clinical research has illuminated both the therapeutic actions and potential hazards of amphetamine administration. Groundbreaking positron emission tomography (PET) studies led by Nora Volkow and colleagues demonstrated that therapeutic oral doses of amphetamines occupy approximately 50% or more of dopamine transporters in the striatum. Crucially, the clearance and dopamine release kinetics of clinical oral formulations mimic a slow, sustained ramp-up, whereas intravenous administration produces rapid striatal surges that correspond directly with subjective “highs” and rapid reinforcement pathways.
The landmark Multimodal Treatment Study of Children with ADHD (the MTA Study) established that stimulant treatment produces dramatic short-term reductions in core ADHD symptoms, superior to behavioral therapy alone. Long-term follow-ups have sparked debate regarding whether these academic and behavioral benefits persist uniformly across decades, highlighting the need for continuous clinical monitoring and individualized dosing.
Regarding long-term neurobiology, pre-clinical animal models demonstrate that sustained, extremely high doses of amphetamines can damage monoaminergic nerve terminals through reactive oxygen species generation, microglial activation, and dopamine auto-oxidation. However, longitudinal neuroimaging studies in human patients with ADHD have shown that long-term, therapeutic-dose treatment does not induce neurotoxic damage; rather, it may normalize underlying structural abnormalities within the basal ganglia and frontostriatal circuits toward control baselines.
12. Cultural & Cross-Cultural Considerations
Societal acceptance and regulatory frameworks regarding amphetamines diverge sharply across global jurisdictions, reflecting contrasting cultural philosophies on psychiatric intervention and drug control:
In the United States, medical prescribing of amphetamines for ADHD is widespread, embedded within a broader cultural paradigm that recognizes neurodevelopmental disorders as treatable neurochemical deficits. Conversely, in many European nations—such as France and the United Kingdom—clinical guidelines historically prioritized psychosocial interventions, maintaining stricter thresholds for initiating stimulant pharmacotherapy. Methylphenidate is generally preferred as the initial agent in these regions, with amphetamines reserved for treatment-resistant presentations.
In parts of East and Southeast Asia, cultural and legal stances toward amphetamines are exceptionally strict. In Japan, the Stimulants Control Act strictly bans the importation, possession, and use of most amphetamines, with exceptions restricted almost entirely to narcolepsy treatment; lisdexamfetamine and Adderall are strictly regulated or prohibited outright. Similarly, in countries like Singapore and the United Arab Emirates, travelers carrying legally prescribed personal supplies of amphetamines risk arrest and imprisonment without prior government clearance, reflecting an uncompromising prohibitionist paradigm that views all amphetamines through the lens of dangerous illicit narcotics.
13. Criticisms, Debates & Limitations
Despite their established efficacy, amphetamines remain subject to significant clinical, societal, and ethical controversies:
A primary concern is diagnostic inflation and subsequent overprescribing. Critics argue that the substantial growth in adult ADHD diagnoses over recent decades is partly driven by aggressive direct-to-consumer advertising, telehealth platforms with inadequate diagnostic standards, and the modern knowledge economy’s demand for sustained attention. This trend raises concerns that normal human variations in attention and stamina are being medicalized to justify stimulant consumption.
Physiologically, long-term cardiovascular safety remains an active area of clinical surveillance. Amphetamines consistently increase resting heart rate by 2 to 5 beats per minute and elevate mean systolic blood pressure by 2 to 4 mmHg. While these changes are well-tolerated by healthy adolescents, concerns persist regarding cumulative cardiovascular risks (including myocardial infarction, stroke, and arrhythmias) in adults with pre-existing vascular pathology who maintain stimulant regimens for decades.
Diversion and non-medical use represent further systemic challenges. Studies indicate that a significant proportion of secondary school and university students with valid stimulant prescriptions are pressured to share, sell, or trade their medication. This illicit diversion circumvents medical risk screening and fuels recreational patterns of use that carry elevated risks of addiction, cardiovascular complications, and psychiatric crises.
14. Related Terms & Distinctions
Understanding amphetamines requires delineating them from structurally and pharmacologically related compounds:
- Methylphenidate: A central nervous system stimulant sharing similar clinical indications (ADHD, narcolepsy). Unlike amphetamine, methylphenidate is a classic dopamine and norepinephrine reuptake inhibitor (NDRI); it blocks DAT and NET without entering the presynaptic neuron, without inducing reverse transport, and without disrupting VMAT2.
- Methamphetamine: A structural analogue possessing an additional methyl group on its terminal nitrogen atom. This chemical modification increases its lipophilicity, allowing it to penetrate the blood-brain barrier far more rapidly. It exhibits significantly higher neurotoxicity toward dopaminergic and serotonergic axon terminals compared to pharmaceutical amphetamine.
- Cocaine: An alkaloid derived from the coca plant. Cocaine acts as a non-selective monoamine reuptake inhibitor (blocking DAT, NET, and SERT) and a local anesthetic via sodium channel blockade. It has a much shorter elimination half-life (approximately 60 to 90 minutes) compared to amphetamine’s typical 10 to 12 hours.
- Modafinil: An atypical wakefulness-promoting agent used primarily for narcolepsy and shift work sleep disorder. While it exerts low-affinity inhibition on DAT, its primary mechanism involves secondary downstream modulation of hypocretin/orexin, histamine, and glutamate signaling, presenting substantially lower euphoric and addictive liability than amphetamines.
- Ephedrine: A naturally occurring sympathomimetic alkaloid derived from Ephedra species. It lacks the synthetic alpha-methyl modification that gives amphetamine its high CNS selectivity; ephedrine acts largely on peripheral adrenergic receptors with relatively weak central psychotropic potency.
15. Summary / Key Takeaways
Amphetamines are potent, synthetic indirect sympathomimetic stimulants that act as substrates for catecholamine transporters, driving the phosphorylation of DAT and NET, disrupting vesicular storage via VMAT2, and inducing reverse transport of dopamine and norepinephrine into the synaptic cleft. This dual mechanism underlies both their profound therapeutic efficacy in conditions like ADHD and narcolepsy—where they enhance frontostriatal executive control and daytime arousal—and their potential for misuse, tolerance, and addiction when taken in high doses or through rapid-onset routes of administration.
The contemporary clinical landscape relies heavily on enantiomeric tailoring (favoring dextroamphetamine) and pharmacokinetic innovations (such as prodrug formulations and extended-release matrices) designed to optimize clinical benefit while minimizing cardiovascular and addictive liabilities. As neuroscientific research continues to clarify individual variations in monoaminergic signaling, amphetamines remain fundamental pharmacological tools in neuropsychiatry, demanding careful clinical oversight, objective diagnostic procedures, and an evidence-based appreciation of their dual potential as therapeutic agents and substances of abuse.
References
- Arnsten, A. F. T. (2009). Toward a new understanding of ADHD: Rethinking the role of the prefrontal cortex. CNS Drugs, 23(Suppl 1), 33–41. https://doi.org/10.2165/00023210-200923000-00005
- Bradley, C. (1937). The behavior of children receiving Benzedrine. American Journal of Psychiatry, 94(3), 577–585. https://doi.org/10.1176/ajp.94.3.577
- Fleckenstein, A. E., Volz, T. J., Riddle, E. L., McCall, J. W., & Hanson, G. R. (2007). New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology, 47, 681–698. https://doi.org/10.1146/annurev.pharmtox.47.120505.105140
- Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247–291. https://doi.org/10.1016/0165-0173(93)90013-P
- Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Hitzemann, R., & Pappas, N. (1998). Dopamine transporter occupancies in the human brain induced by normal therapeutic doses of oral methylphenidate. American Journal of Psychiatry, 155(10), 1325–1331. https://doi.org/10.1176/ajp.155.10.1325